S-1/A: Dror Ortho-Design Files Amended S-1 for Public Offering, Highlighting AI-Powered Orthodontic Platform and Going Concern Risks

Dror Ortho-Design, Inc., a development-stage company, filed an amended S-1 registration statement to offer up to 2,020,203 shares of common stock and warrants, aiming to raise approximately $8.9 million for working capital and general corporate purposes, while facing significant operating losses and a going concern warning.

Summary

• Dror Ortho-Design, Inc. is a development-stage company focused on an AI-based orthodontic platform called ZSmile, designed for discreet, less painful smile correction using a single smart aligner with pulsating air, primarily for nighttime use.
• The company is offering up to 2,020,203 shares of common stock at an assumed public offering price of $4.95 per share, along with prefunded warrants and underwriter warrants.
• Net proceeds from the offering are estimated at approximately $8.9 million, or $10.3 million if the over-allotment option is fully exercised, intended for working capital and general corporate purposes.
• A 1-for-450 reverse stock split is expected to be effected prior to or upon the effectiveness of the registration statement.
• The company's first-generation product, Aerodentis System, received FDA 510(k) clearance in April 2020, but the updated ZSmile Platform requires a new 510(k) clearance, which is expected to be filed prior to the end of 2025.
• Dror Ortho-Design currently does not generate revenues and has incurred net losses of $5.8 million in 2024 and $3.6 million in 2023, with an accumulated deficit of $20.08 million as of March 31, 2025.
• Cash used in operations was $499,593 for the three months ended March 31, 2025, and $2,741,822 for the year ended December 31, 2024.
• The company had a cash balance of $349,851 as of March 31, 2025, and its auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity.
• The global clear aligners market was estimated at $6.29 billion in 2022 and is projected to reach $46.3 billion by 2030, growing at a CAGR of 28.34%.
• The company believes its total addressable market for ZSmile, focusing on 'social six' teeth, could reach 22 million people by 2028.

Sentiment

Score: 3

Explanation: The company is in a very early development stage with no revenues and significant recurring losses, raising substantial doubt about its ability to continue as a going concern. While it has innovative technology and a large target market, the path to commercialization is uncertain and dependent on future regulatory approvals and capital raises. The current financial state is precarious, and the offering is critical for its survival.

Positives

• Developed a proprietary AI-based platform (ZSmile) for smile correction, offering a discreet, less painful alternative to existing aligner solutions.
• Holds several patents for the technology used in the Platform, including pulsating air movement, diagnostic process, and 3D printing.
• The predecessor Aerodentis System received FDA 510(k) clearance in April 2020 as a Class II medical device, demonstrating prior regulatory success.
• Targets a large and underserved global clear aligners market, estimated to grow from $6.29 billion in 2022 to $46.3 billion by 2030 (28.34% CAGR).
• The ZSmile Platform is designed to be used by both orthodontists and general dentists, expanding its target distribution channel.
• Believes its image analysis of smartphone videos will eventually approach the accuracy of intraoral scans, potentially increasing efficiency and treatment delivery in the dental industry.
• The use of a single smart aligner for each patient allows for cost-effective 3D printing production, which is superior in precision and customizability compared to traditional thermoforming.
• The company has a research and development team with expertise in AI, medical device development, data science, and 3D printing, including professionals from elite intelligence units of the Israeli Defense Force.
• Management has secured bridge loans of $300,000 from existing investors during the three months ended March 31, 2025, indicating continued investor support.

Negatives

• The company is in the development stage, currently generates no revenues, and has no operating history as a manufacturer and distributor of orthodontic medical devices or platforms for consumer use.
• Incurred significant net operating losses: $576,123 for Q1 2025, $5.8 million for 2024, and $3.6 million for 2023, with an accumulated deficit of $20.08 million as of March 31, 2025.
• Auditor expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient liquidity.
• The new ZSmile Platform requires a new FDA 510(k) clearance, which has not yet been filed, and there is no assurance it will be approved or that market acceptance will be achieved.
• Faces intense competition from large, internationally established aligner companies with greater resources and existing channels.
• The company's common stock is currently traded on the OTC Pink Limited Market, which has limited liquidity, and there is no assurance of successful listing on NYSE American.
• The management team lacks U.S. public company experience, which may impair compliance with U.S. securities laws and GAAP.
• The company is subject to penny stock rules, making its shares more difficult to sell and potentially limiting trading activity.
• The company's operations are conducted in Israel, exposing it to economic, political, geopolitical, and military risks, including the ongoing conflict with Hamas and Hezbollah.

Risks

• Inability to raise additional capital to fund operations, leading to potential delays, reductions, or elimination of R&D programs, asset sales, or mergers.
• Operations and financial performance are vulnerable to global and regional economic conditions, including inflation, currency fluctuations, and recessions.
• Products and technologies may not be accepted by intended commercial consumers or achieve widespread market acceptance.
• Continued operating losses are expected, and future profitability is uncertain.
• Net revenues will depend primarily on the ZSmile Platform, and any decline in sales or average selling price could adversely affect financial performance.
• Competition from large, established aligner companies and new entrants could render the company's technology obsolete or economically unattractive.
• Business model depends on reaching consumers through social media, which may not be successful or cost-effective in the long term.
• Future sales may depend on customers' ability to obtain reimbursement from third-party payors, which could negatively impact revenues and gross margin.
• Adverse changes in, or interpretations of, laws and regulations governing remote healthcare and dentistry could disrupt the business model.
• Failure to comply with FDA and other regulatory authorities' regulations could result in substantial penalties, product recalls, or inability to market products.
• Certain modifications to products may require new 510(k) clearance or other marketing authorizations, leading to delays or denials.
• Ongoing changes in healthcare regulation could negatively affect revenues, business, and financial condition.
• Subject to federal, state, and foreign fraud and abuse laws, health information privacy and security laws, and transparency laws, with potential for substantial penalties for violations.
• Inability to successfully enforce intellectual property rights could harm competitive position.
• Lack of U.S. public company experience of the management team may put the company at a competitive disadvantage.
• Limited trading market for common stock and potential for wide fluctuations in stock price.
• Exposure to potential liability for product quality, safety, advertising, and sales practices, leading to substantial expenses or damages.
• Increased focus on ESG laws and scrutiny of ESG policies may increase costs, expose to liability, and impact reputation.
• Risks related to credit card and debit card payments, including fees, fraud, and compliance with payment card association rules.
• Risks related to future international sales, including the need for foreign regulatory clearances and challenges to the teledentistry model.
• Security breaches, data breaches, cyber attacks, or failure to comply with privacy laws could materially impact operations and reputation.
• Changes in accounting rules and regulations could result in unfavorable accounting charges.
• Material weakness in internal control over financial reporting, potentially affecting financial reporting accuracy and compliance.
• Effective tax rate may vary significantly due to global economic changes, tax law changes, and audit outcomes.

Future Outlook

The company expects to continue incurring significant operating losses as it develops its ZSmile Platform and does not anticipate generating revenues until successful development and testing are complete. It plans to file the 510(k) submission for the Platform prior to the end of 2025. Future success depends on market acceptance of its products and ability to raise additional capital. The company intends to apply for listing on NYSE American, which is a condition for proceeding with the current offering.

Management Comments

• "We have reimagined the way people can correct their smile. We plan to disrupt the aligner market by offering millions of people a revolutionary alternative."
• "We believe that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions, Existing aligner solutions generally share the same treatment principles, which are different from our solution."
• "Our Company has developed a proprietary AI-based solution to correct peoples smiles in a discreet and less painful manner (the Platform)."
• "We expect to file the 510(k) submission for the Platform prior to the end of 2025."
• "The Company currently does not generate revenues to fund operations and anticipates that it will continue to incur significant losses as it continues to develop the Platform."
• "The Company intends to spend approximately $1.5 million over the next 18 months on software and hardware development as well as the accompanying regulatory approvals and IP protection associated with such software and hardware projects."
• "Management does not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented."
• "It is the present intention of our board of directors to retain future earnings for the development, operation, and expansion of our business, and our board of directors does not anticipate declaring or paying any cash dividends for the foreseeable future."

Industry Context

Dror Ortho-Design is entering the rapidly transforming dental industry, specifically the clear aligners market, which is projected for substantial growth from $6.29 billion in 2022 to $46.3 billion by 2030. The company aims to disrupt this market with its AI-based, single-aligner, nighttime treatment solution, differentiating itself from traditional multi-aligner systems like Invisalign. Its strategy aligns with the growing trend of teledentistry and general dentists providing orthodontic care, expanding the potential distribution channels beyond orthodontists.

Comparison to Industry Standards

• **Treatment Method:** Unlike traditional clear aligner solutions (e.g., Invisalign by Align Technology, Byte by Dentsply Sirona, 3M Clarity Aligners, Straumann Group) that require patients to wear multiple plastic aligners all day for 12-15 months, Dror Ortho-Design's ZSmile Platform uses only one smart aligner with pulsating air, primarily for nighttime use, aiming for a less painful and less intrusive experience.
• **Technology:** While competitors rely on continuous resistant force, ZSmile utilizes patented pulsating air technology, which is claimed to improve blood circulation and facilitate tooth movement more gently.
• **Manufacturing:** Traditional aligners are produced via thermoforming, requiring multiple aligners per patient. ZSmile's single-aligner approach enables cost-effective 3D printing for the actual aligners, offering superior precision and customizability, a method not financially viable for multi-aligner systems.
• **Market Focus:** ZSmile is optimized for 'social six' malocclusions (front upper and lower six teeth), potentially addressing a specific segment of the broader orthodontic market.
• **Distribution Channel:** The ZSmile Platform is designed for use by both orthodontists and general dentists, leveraging the trend of dentists performing orthodontic procedures (36% of dentists in a 2019 study), which expands its target distribution channel compared to solutions primarily focused on orthodontists.
• **Regulatory Status:** While competitors have established market presence and regulatory clearances, Dror Ortho-Design's new ZSmile Platform requires a new FDA 510(k) clearance, which is a critical hurdle for market entry, unlike its first-generation Aerodentis System which was already cleared.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be subject to routine litigation incidental to its business from time to time.
• Management believes that there are no current matters, individually or in the aggregate, that would have a material adverse effect on the results of operations and financial condition.

Related Party Transactions

• **Share Exchange (August 14, 2023):** Private Dror shareholders, including Moshe Shvets (CTO and director), AIGH Investment Partners (5%+ beneficial owner), exchanged their shares for 7,576,999 shares of Series A Preferred Stock and 106,782,187 shares of Common Stock of Dror Ortho-Design, Inc.
• **Private Placement (August 14, 2023, and September 13, 2023):** Eliyahu Haddad (CEO and director), Moshe Shvets, and AIGH Investment Partners participated, receiving Common Stock, Series A Preferred Stock, and Private Placement Warrants. Mr. Haddad received Series A Preferred Stock convertible into 4,545,454 shares of Common Stock and warrants for 4,545,454 shares. AIGH received Series A Preferred Stock convertible into 305,454,385 shares of Common Stock, 40,000,000 shares of Common Stock, and warrants for 203,000,000 shares. Mr. Shvets received Series A Preferred Stock convertible into 69,162,094 shares of Common Stock and warrants for 26,141,712 shares.
• **Registration Rights Agreement Amendment (August 13, 2024):** The company agreed to pay Private Placement Investors $520,000 in liquidated damages for delays in filing and effectiveness of the registration statement.
• **Consulting Agreement with Yehuda Englander (Director):** Mr. Englander receives a monthly cash fee of $2,500 (amended from NIS 3,500) for financial and strategic consulting services, plus expense reimbursements up to $500. He was also granted options to purchase 9,597,675 shares of Common Stock.
• **Consulting Agreement with Chaim Ravad (Director):** Mr. Ravad received a cash fee of $5,000 per month for board member services, totaling $55,000, which concluded the agreement.
• **Consulting Agreement with Oriole Avenue Inc. (Shareholder):** Oriole, an entity owned by Yaacov Bodner (5%+ stockholder), received $145,000 in cash payments and warrants to purchase 10,454,500 shares of Common Stock for shareholder, investor relations, and general consultancy services.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience significant dilution from the current offering and potential future capital raises. The reverse stock split will reduce the number of outstanding shares but increase the per-share price, potentially affecting market perception and liquidity. The going concern warning indicates a high risk of loss of investment.
• **New Investors:** New investors will face immediate dilution of $3.03 per share based on the assumed offering price, and their investment is highly speculative due to the company's development stage, lack of revenue, and significant losses.
• **Employees:** The company's ability to continue operations and fund R&D directly impacts employee job security and future compensation. The ongoing conflict in Israel could affect employees subject to military service.
• **Customers (Future):** The success of the ZSmile Platform depends on its acceptance by dental professionals and consumers. Delays in FDA clearance or market acceptance could impact the availability and quality of the product for future customers.
• **Suppliers/Vendors:** The company's reliance on outsourced third-party vendors for R&D and manufacturing means that disruptions to these relationships or their operations (e.g., due to conflict in Israel) could adversely affect product development and supply chain.
• **Creditors:** The company's recurring losses and going concern status indicate a high risk for creditors, as its ability to repay debt is dependent on future capital raises and commercial profitability.

Next Steps

• Effect a 1-for-450 reverse stock split prior to or upon effectiveness of the registration statement.
• Apply to have Common Stock listed for trading on the NYSE American.
• File the 510(k) submission for the ZSmile Platform prior to the end of 2025.
• Spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection.
• Raise additional equity or debt capital to fund operations and continue as a going concern.
• Develop and introduce new products and services to enhance the Platform.
• Attract and retain key orthodontists, dentists, and dental organizations to work with the company.
• Monitor and comply with evolving healthcare regulations, including those related to teledentistry and data privacy.
• Remediate the identified material weakness in internal control over financial reporting.

Key Dates

Recommendation

Keywords

Orthodontics, Clear Aligners, AI-based Platform, ZSmile, Aerodentis System, Medical Device, FDA Clearance, 510(k) Submission, Teledentistry, Dental Technology, Reverse Stock Split, Public Offering, SEC Filing, Going Concern, Startup, Intellectual Property, Israel Operations, OTC Pink Market, NYSE American Listing